Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans.

Podoll T, Pearson PG, Evarts J, Ingallinera T, Bibikova E, Sun H, Gohdes M, Cardinal K, Sanghvi M, Slatter JG.

Drug Metab Dispos. 2019 Feb;47(2):145-154. doi: 10.1124/dmd.118.084459. Epub 2018 Nov 15.

PMID:
30442651
2.

Multi-layered analyses using directed partitioning to identify and discriminate between biogenic amines.

Nelson TL, Tran I, Ingallinera TG, Maynor MS, Lavigne JJ.

Analyst. 2007 Oct;132(10):1024-30. Epub 2007 Jul 26.

PMID:
17893806
3.
4.

Assuring quality and performance of sustained and controlled release parenterals: workshop report.

Burgess DJ, Hussain AS, Ingallinera TS, Chen ML.

AAPS PharmSci. 2002;4(2):E7.

5.

Development and validation of an HPLC assay for fentanyl and related substances in fentanyl citrate injection, USP.

Lambropoulos J, Spanos GA, Lazaridis NV, Ingallinera TS, Rodriguez VK.

J Pharm Biomed Anal. 1999 Aug;20(4):705-16.

PMID:
10704140
6.

Compatibility of glycopyrrolate injection with commonly used infusion solutions and additives.

Ingallinera TS, Kapadia AJ, Hagman D, Klioze O.

Am J Hosp Pharm. 1979 Apr;36(4):508-10. No abstract available.

PMID:
433937

Supplemental Content

Loading ...
Support Center